Our Pricing

Wegovy vs Mounjaro: Key Differences & UK Pricing

Published on: June 03, 2026

If you're researching a mounjaro vs wegovy uk price comparison, you're likely weighing two of the most effective prescription weight loss treatments available today. Both are weekly injectable medications licensed by the MHRA, but they differ in active ingredient, mechanism of action, clinical efficacy, and cost. At Cured Pharmacy, we provide transparent pricing, UK prescriber consultations, and discreet delivery for both treatments, helping you make an informed choice based on clinical evidence and your individual health profile.

Mounjaro vs Wegovy UK: Active Ingredients and Mechanisms

Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, meaning it activates two hormone pathways that regulate appetite, blood sugar, and energy metabolism [1]. Wegovy, by contrast, contains semaglutide, a single GLP-1 receptor agonist that has been widely studied and used in the UK since 2022 [2].

The dual-action mechanism of tirzepatide distinguishes Mounjaro from all other currently licensed weight loss injections. By targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors, Mounjaro produces more pronounced reductions in appetite and body weight in clinical trials compared to single-pathway treatments [1][3].

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. Each requires gradual dose escalation over several weeks to minimise gastrointestinal side effects, and both are prescription-only medicines in the UK, requiring clinical assessment by a registered prescriber before dispensing.

Clinical Efficacy: Mounjaro vs Wegovy Weight Loss Results

In head-to-head comparisons and separate large-scale trials, Mounjaro has demonstrated superior weight loss outcomes. The SURMOUNT-1 trial showed that adults using the highest dose of tirzepatide (15 mg) achieved an average weight reduction of 22.5% over 72 weeks, compared to placebo [1]. The STEP 1 trial, which evaluated semaglutide 2.4 mg (Wegovy), reported an average weight loss of 14.9% over 68 weeks [2].

A direct comparison study published in 2024 confirmed tirzepatide's greater efficacy: patients on Mounjaro lost approximately 6% more body weight on average than those on Wegovy after one year of treatment [3]. Both treatments, however, significantly outperform older weight loss medications and lifestyle interventions alone.

Individual results vary based on baseline weight, adherence to treatment, dietary habits, physical activity, and metabolic factors. Your UK prescriber will assess your medical history, current medications, and weight loss goals to determine which treatment may be more suitable for you.

Who Responds Best to Each Treatment?

Clinical trials indicate that both Mounjaro and Wegovy are effective across a broad range of patients with a BMI of 30 or above, or 27 or above with weight-related comorbidities such as type 2 diabetes, hypertension, or sleep apnoea [1][2]. Patients with type 2 diabetes may experience additional glycaemic benefits from tirzepatide due to its dual-receptor action, though both medications improve HbA1c levels.

Those who have previously used liraglutide (Saxenda) or other GLP-1 treatments and experienced suboptimal weight loss may benefit from switching to Mounjaro, given its enhanced mechanism and clinical outcomes. Your prescriber will consider your treatment history, tolerance to GLP-1 side effects, and individual response when recommending a medication.

Mounjaro vs Wegovy UK Pricing and Value

At Cured Pharmacy, Mounjaro is priced from £124.99 per pen, and Wegovy starts from £135.00 per pen, with final costs determined by your prescribed dose following a free online consultation with a UK prescriber. These prices reflect our commitment to transparent, competitive pricing and include clinical assessment, prescription, and discreet UK delivery.

While Mounjaro carries a higher per-pen cost, many patients and prescribers consider the additional investment justified by the greater average weight loss observed in clinical trials. Wegovy remains an excellent option for those seeking effective weight management at a lower price point, particularly if budget is a primary concern or if clinical trials suggest similar efficacy for your profile.

Neither medication is currently available on the NHS for weight management alone in most areas due to supply constraints and commissioning decisions, though exceptions exist for patients with type 2 diabetes or specific clinical criteria. Private prescriptions through registered UK pharmacies like Cured Pharmacy offer reliable access to both treatments without waiting lists.

Side Effects: What to Expect from Mounjaro and Wegovy

Both Mounjaro and Wegovy share a similar side effect profile, as both are GLP-1 receptor agonists. The most commonly reported adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during the initial dose escalation phase [1][2]. These symptoms typically improve over several weeks as your body adjusts to the medication.

In clinical trials, approximately 10-20% of participants on tirzepatide and 5-15% on semaglutide discontinued treatment due to gastrointestinal side effects [1][2]. Gradual dose titration, eating smaller meals, and avoiding high-fat foods can help minimise these effects. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not confirmed in humans).

Your UK prescriber will review your medical history for contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both medications are contraindicated in pregnancy, and effective contraception is advised during treatment. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis, seek immediate medical attention.

Managing Side Effects Effectively

Most patients find that nausea and gastrointestinal symptoms resolve within 4-6 weeks of starting treatment or increasing doses. Eating slowly, choosing bland and low-fat foods, staying well-hydrated, and avoiding large meals can significantly reduce discomfort. If side effects persist or worsen, your prescriber may adjust your dose or recommend an alternative treatment.

Both Mounjaro and Wegovy are generally well-tolerated when used under medical supervision. Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), is available to support you throughout your treatment journey and answer any questions about managing side effects or optimising your results.

How to Start Mounjaro or Wegovy at Cured Pharmacy

Starting treatment with Mounjaro or Wegovy at Cured Pharmacy is straightforward and discreet. Begin by completing our free online consultation, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Your responses are reviewed by a UK-registered prescriber, who will determine whether Mounjaro, Wegovy, or another treatment is suitable for you.

If approved, your prescription is issued electronically and dispensed by our UK-registered pharmacy team. Your medication is packaged discreetly and delivered to your address via secure courier, typically within 1-3 working days. All medications supplied by Cured Pharmacy are genuine, UK-licensed products sourced from reputable manufacturers and stored in accordance with MHRA guidelines.

You will receive clear instructions on how to administer your injections, store your pens, and escalate your dose safely. Our team is available by phone ((+44) 116 4646009) or email to answer any questions before, during, or after your treatment. Follow-up consultations are available to monitor your progress, adjust doses, or switch treatments if needed.

Mounjaro vs Wegovy: Which Should You Choose?

Choosing between Mounjaro and Wegovy depends on your weight loss goals, budget, medical history, and tolerance to GLP-1 medications. If maximising weight loss is your primary objective and you are comfortable with a higher investment, Mounjaro's dual-action mechanism and superior trial outcomes make it a compelling choice [1][3]. If cost is a significant factor or you have previously responded well to single-pathway GLP-1 treatments, Wegovy offers proven efficacy at a more accessible price point [2].

Both medications require commitment to a healthy diet, regular physical activity, and long-term adherence to maintain results. Weight regain is common if treatment is discontinued without ongoing lifestyle modification. Your UK prescriber will discuss realistic expectations, potential side effects, and strategies for sustaining weight loss beyond the medication period.

At Cured Pharmacy, we provide unbiased clinical guidance to help you select the treatment best suited to your individual circumstances. Our transparent pricing, UK-registered clinical team, and commitment to patient safety ensure you receive expert care from consultation through to delivery and beyond.

Combining Treatment with Lifestyle Changes

Both Mounjaro and Wegovy are most effective when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating significant weight loss included structured lifestyle interventions alongside medication [1][2]. Your prescriber may recommend working with a dietitian, joining a weight management programme, or setting specific activity goals to optimise your results.

Long-term success requires sustainable behavioural changes. While these medications reduce appetite and support initial weight loss, maintaining your results depends on continued healthy eating patterns, regular exercise, and ongoing medical support. Our team at Cured Pharmacy is here to support your journey every step of the way.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and physical activity levels.